MYC and neoplasm: In vivo results further demonstrated that siFAK + CRISPR-LNPs decreased metastatic potential in an ovarian cancer mouse model, improved outcomes in a tumor xenograft mouse model, and extended survival in an aggressive MYC-driven liver cancer model, highlighting significant anti-tumor effects across different cancer types.